Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Conestat Alfa · Ruconest

Recombinant protein · Protein replacement: Plasma kallikrein (KLKB1), Complement component 1s (C1s) (C1S) and Coagulation factor XIIa (F12) · developed by Pharming Healthcare

Approved FDA, Jul 2014
PHAR Developer
2 Registered trials

What is Conestat Alfa?

Conestat alfa is a recombinant form of human C1 esterase inhibitor, a serine protease inhibitor. It irreversibly binds and inhibits several proteases of the contact and complement systems, including activated C1s, kallikrein, factor XIIa and factor XIa, reducing bradykinin production and vascular permeability. It is used in hereditary angioedema and is studied in coronavirus infections, acute ischemic stroke and acute renal injury.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ruconest
Drug type
Recombinant protein
Targets
Plasma kallikrein (KLKB1), Complement component 1s (C1s) (C1S), Coagulation factor XIIa (F12), Coagulation factor XIa (F11)
Mechanism
Protein replacement: Plasma kallikrein (KLKB1), Complement component 1s (C1s) (C1S) and Coagulation factor XIIa (F12)
Pathways
contact system activation, complement system activation, bradykinin production, vascular permeability
Therapy area
Cardiovascular, Infectious disease, Neurology, Renal & urology
Developer
Pharming Healthcare Inc. (PHAR)
FDA status
Approved as Ruconest (July 16, 2014), BLA125495 · FDA label
UNII
5QS67N4551

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 30, 2020). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05145283 Phase 2 Acute Ischemic Stroke Completed PHAR
NCT04414631 Phase 2 Coronavirus Infections Terminated PHAR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Ischemic StrokeAcute Renal InjuryCoronavirus Infections

Other drugs acting on KLKB1 / C1S / F12 / F11

More from Pharming Healthcare

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAR page.

Follow PHAR, the company behind Conestat Alfa

See PHAR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PHAR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.